CYGNOS BioTech to Present Innovative PVX Antiviral Platform at U.S. DoD and International Scientific Conference
Miami, FL – July 8, 2025 — CYGNOS BioTech is pleased to announce a series of upcoming scientific presentations highlighting the development of PVX, a novel host-directed, broad-spectrum antiviral therapeutic currently funded under a Small Business Innovation Research (SBIR) contract from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
CYGNOS will present PVX data at the 2025 Military Health System Research Symposium (MHSRS), the Department of Defense’s premier scientific meeting for military medical research, held at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida, on August 4, 2025. The session, titled “Broad-Spectrum Viral Countermeasures,” will focus on advanced approaches to infectious disease threats relevant to defense and civilian applications.
Following MHSRS, CYGNOS will present new findings at the 19th Annual Botulinum Research Symposium, hosted by the Institute of Advanced Sciences at the Wamsutta Club in New Bedford, Massachusetts. In October 2025, CYGNOS will also participate in the 3rd International Online Conference on Toxins, organized by the peer-reviewed open-access journal Toxins (MDPI), presenting on the translational aspects of PVX in toxin-modulated disease pathways.
These upcoming conferences provide a platform for CYGNOS to share recent mechanistic, bioanalytical, and translational findings, while also engaging new research collaborators, funding partners, and clinical advisors.
For more information or partnership inquiries about our novel infectious disease and oncology products in development for veterinary and human use, please contact John A. Bogdan, Ph. D., VP of Product Development and Partnering at john.bogdan@cygnosbiotech.com or visit www.cygnosbiotech.com.
Reference to the Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, or other agency of the United States does not constitute or imply an endorsement or recommendation by the United States government or any agency thereof.